ASLAN Pharmaceuticals (NASDAQ:ASLN) vs. Eliem Therapeutics (NASDAQ:ELYM) Head to Head Analysis

Risk and Volatility

Eliem Therapeutics has a beta of -0.39, indicating that its share price is 139% less volatile than the S&P 500. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500.

Valuation & Earnings

This table compares Eliem Therapeutics and ASLAN Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12 million	($0.53)	-24.60
ASLAN Pharmaceuticals	$12.00 million	0.10	-$44.22 million	($21.92)	-0.03

Eliem Therapeutics has higher earnings, but lower revenue than ASLAN Pharmaceuticals. Eliem Therapeutics is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Eliem Therapeutics and ASLAN Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%

Institutional and Insider Ownership

69.8% of Eliem Therapeutics shares are held by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. 4.7% of Eliem Therapeutics shares are held by insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Eliem Therapeutics beats ASLAN Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

About Eliem Therapeutics

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.